The story of the erectile dysfunction drug presents a intricate picture for those considering investment. While the initial introduction generated significant gains, the expiration of its intellectual property protection opened the floodgates to off-brand versions, dramatically reducing revenue. This poses a particular dilemma for drug manufacturer

The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in sales , its intellectual property lapse created a flood of knock-off medications, significantly eroding its dominance. While specific firms may attempt to capitalize on similar conditions , the curr